Approach: We will test how the human transcription factor CREM (cAMP responsive element modulator) protects from colitis due to Entamoeba histolytica and inflammatory bowel disease (IBD). Successful completion of these studies will identify how and where CREM acts to guard against bowel injury. Significance: The importance of this project derives from the contribution of amebiasis to diarrhea in children in the developing world and to the estimated one million Americans who suffer from IBD. Understanding how CREM protects may provide new approaches to the currently inadequate treatments of amebic colitis and IBD. Progress: The past 5 years of support advanced the understanding of amebic colitis and resulted in 26 original research papers, including Nature, Nature Microbiology, Scientific Reports and Cell Reports, and publication of 17 reviews. Innovative aspects of the proposal include that cAMP-regulated gene expression has not previously been considered to contribute to defense of the intestine. The environment for the work is a parasitology lab with ongoing investigation of amebiasis in humans, murine models and at the cellular level, which is led by the Principal Investigator with 3 decades of amebiasis research experience.

Public Health Relevance

This project investigates how a human transcription factor named CREM protects from amebic colitis. We have discovered a genetic mutation in CREM that is associated with susceptibility to both Entamoeba histolytica colitis as well as inflammatory bowel disease (IBD). We will test the hypothesis that CREM defends from amebic colitis and IBD by activating the expression of genes that protect or help heal the intestine from injury. The work is important because current therapies are limited for amebic colitis (a cause of child deaths from diarrhea in low income countries) and for IBD (a disease that affects over a million Americans). Understanding how CREM protects will provide new approaches to the treatment of amebic colitis and inflammatory bowel disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI026649-29
Application #
9624379
Study Section
Pathogenic Eukaryotes Study Section (PTHE)
Program Officer
Pesce, John T
Project Start
1989-08-01
Project End
2022-12-31
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
29
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wojcik, Genevieve L; Marie, Chelsea; Abhyankar, Mayuresh M et al. (2018) Genome-Wide Association Study Reveals Genetic Link between Diarrhea-Associated Entamoeba histolytica Infection and Inflammatory Bowel Disease. MBio 9:
Buonomo, Erica L; Madan, Rajat; Pramoonjago, Patcharin et al. (2013) Role of interleukin 23 signaling in Clostridium difficile colitis. J Infect Dis 208:917-20